Review Article



Medicare Annual Wellness Visits: A Scoping Review of Current Practice Models and Opportunities for Pharmacists

Journal of Pharmacy Practice 1-16 © The Author(s) 2019 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/0897190019847793 journals.sagepub.com/home/jpp

\$SAGE

Lindsey A. Hohmann, PharmD¹, Tessa J. Hastings, MS¹, Jingjing Qian, PhD¹, Geoffrey M. Curran, PhD^{2,3}, and Salisa C. Westrick, PhD¹

Abstract

Objective: To explore the existing practice models and practice opportunities surrounding pharmacist-delivered Medicare Annual Wellness Visits (AWVs), with the goal of improving patient access through advanced pharmacy-based health services. Data Sources: English-language articles published in peer-reviewed journals from January 2011 to March 2018 were reviewed by searching PubMed and Google Scholar databases using permutations of terms such as "pharmacist/pharmacy," "Medicare," "Annual Wellness Visit," "develop/development," and "implement/implementation." Study Selection and Data Extraction: Original articles reporting resources (inputs), processes, and programmatic outcomes (uptake and delivery, interventions made, financial models, satisfaction) of pharmacist-delivered AWV services were retained. Data Synthesis: Eight articles describing 6 unique studies representing current pharmacist-delivered AWV practices were included in the final review. All identified articles used observational study designs and were published in peer-reviewed journals from 2014 to 2017. Five studies utilized staff (in-house) pharmacists working in internal or family medicine clinics via collaborative practice agreements; one study described a model for outsourcing AWV services through a community pharmacy. Pharmacists completed 37 to 300 AWVs and performed both medication- and non-medication-related interventions, with a mean of 3.5 to 5.4 interventions/patient. Quarterly revenue ranged from \$3750 to \$22 340 (USD), with 40 pharmacist-hours required for initial program development. Implications for Patient Care and Clinical Practice: This scoping review will serve as a guide for pharmacists wishing to implement AWV services in their own practices. Conclusions: There is opportunity for ambulatory/community pharmacists to expand their practices to include AWV services in states that allow collaborative practice agreements. Interprofessional collaboration between physicians and pharmacists can optimize and aid adoption of pharmacist-delivered AWV services.

Keywords

preventative medicine, community pharmacy, family medicine, health-care policy, geriatrics

Background

Chronic Conditions and Preventive Services

Preventive health care is increasingly important in today's medical landscape. 1,2 Chronic conditions like diabetes and heart disease are highly prevalent, with almost 120 million Americans having at least one chronic condition in 2012 and 25% having multiple chronic conditions. In addition to increased mortality and decreased quality of life resulting from these conditions, the financial burden to patients and the health-care system is huge, leading to \$260 billion in lost productivity per year and over \$2 trillion in health-care expenditures. 1,4,5 Services such as diabetes screenings, cardiovascular disease screenings, and wellness examinations could help prevent some of the morbidity, mortality, and economic burden associated with these chronic conditions. 1,6 However, research has shown that lack of access and high cost sharing limit patients'

utilization of these preventive services in some cases. $^{1,7-10}$ Indeed, utilization of preventive screenings has been shown to increase by almost 10% when cost sharing like co-pays and deductibles is waived. 1,8,10

Corresponding Author:

Salisa C. Westrick, Department of Health Outcomes Research and Policy, Auburn University Harrison School of Pharmacy, 020 James E. Foy Hall, Auburn, AL 36849, USA.

Email: westrsc@auburn.edu

¹ Department of Health Outcomes Research and Policy, Auburn University Harrison School of Pharmacy, Auburn, AL, USA

² Department of Pharmacy Practice, University of Arkansas for Medical Sciences, Little Rock, AR, USA

³ Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Table 1. Free Preventive Services Offered Through Medicare Part B.

All Medicare Part B Preventive Services

- 1. Advance Care Planning (ACP) as an optional element 13. Human immunodeficiency virus (HIV)
- 2. Alcohol misuse screening and counseling
- 3. Annual wellness visit (AWV)
- 4. Bone mass measurements
- 5. Cardiovascular disease screening
- 6. Colorectal cancer screening
- 7. Counseling to prevent tobacco use
- 8. Depression screening
- 9. Diabetes screening
- 10. Diabetes self-management training (DSMT)
- 11. Glaucoma screening
- 12. Hepatitis C virus (HCV) screening

- screening
- 14. Influenza, pneumococcal, and hepatitis B vaccinations and their administration
- 15. Intensive behavioral therapy (IBT) for cardiovascular disease (CVD), also known as a CVD risk reduction visit
- 16. Intensive behavioral therapy (IBT) for obesity
- 17. Welcome to Medicare visit or Initial Preventive Physical Examination (IPPE)
- 17. Welcome to Medicare visit or Initial Preventive Physical Examination (IPPE)
- 18. Medical nutrition therapy (MNT)
- 19. Prostate cancer screening

- 20. Screening for cervical cancer with human papillomavirus (HPV) tests
- 21. Screening for lung cancer with low dose computed tomography (LDCT)
- 22. For sexually transmitted infections (STIs) and high-intensity behavioral counseling (HIBC) to prevent STIs
- 23. Screening mammography
- 24. Pap tests
- 25. Screening pelvic examination (includes clinical breast examination)
- 26. Ultrasound screening for abdominal aortic aneurysm (AAA)

Basic Components of Medicare Part B Wellness Examinations

Initial Preventive Physical Examination (IPPE)

Annual Wellness Visit (AWV)

Eligibility: Enrolled < I year

Components

- I. Acquire patient information
 - Review medical history, risk factors, functional ability

2. Assess patient

- Assess routine measures
- Discuss end-of-life planning if desired by patient
- 3. Counsel patient
 - · Educate, counsel, refer based on previous steps/findings
 - Create a brief written plan/checklist for the patient to obtain other preventive services (once-per-lifetime ECG, etc) as appropriate

Billing: File claims with Medicare Part B using HCPCS codes

- G0402: face-to-face IPPE visit
- G0403/404/405: ECG performed as part of the
- Plus ICD-9/10 consistent with the examination

Eligibility: Enrolled $\geq I$ year

Components

- I. Acquire/update patient information
 - Administer/update a health risk assessment (HRA) before or during the visit (\sim 20 minutes). This includes patients' demographic information and self-assessment of health status and may be completed in-person, by mail, or telephone
- 2. Assess patient
- Assess routine measures
- Screen for cognitive impairment

3. Counsel patient

- Establish/update a written screening schedule for the next 5 to 10 years, based on appropriate preventive services for age and health status/history (patient report)
- Provide appropriate referrals to health education or preventive programs (eg, tobacco cessation)
- Review advance care planning services at the patient's discretion

Billing: File claims with Medicare Part B using HCPCS codes

- G0438: Initial (1st) AWV
- G0439: Subsequent AWVs
- Plus ICD-9/10 consistent with the exam

Abbreviations: ECG, electrocardiogram; ICD-9/10, international classification of diseases, ninth/tenth revision.

Recognizing the importance of preventive services, the US Affordable Care Act (ACA) of 2010 aimed to alleviate this problem by mandating that private insurers cover certain preventive health services at no charge to the patient. 1,11 Examples of these services included women's wellness examinations and domestic violence counseling. The ACA, in conjunction with the Medicare Improvement for Patients and Providers Act of 2008, also established preventive health services for older adults and certain disabled individuals enrolled in Medicare.1 In fact, Medicare Part B (Medicare's optional outpatient medical insurance program for disabled individuals and older adults ≥65 years) offers 26 preventive health services for which coinsurance and deductibles are waived for the enrollee (Table 1). 12,13 A broad array of services are offered, including

diabetes screening, medical nutrition therapy, mammograms, and prostate cancer screening. 12,13 Key among these preventive services are the Initial Preventive Physical Examination (IPPE; also known as the Welcome to Medicare visit) and the Annual Wellness Visit (AWV). These wellness examinations/consultations are offered during the first and subsequent years of enrollment in Medicare Part B, respectively, with the goals of identifying, providing, or recommending needed preventive health services; thus, these visits provide a medium to assist enrollees in identifying and receiving appropriate preventive care from among the plethora of options offered through Medicare Part B. 12,13 According to current Medicare guidelines, IPPEs can only be provided by physicians and qualified nonphysician practitioners including nurse practitioners and

physician assistants; however, AWVs can also be provided by additional licensed medical professionals, including pharmacists, and will thus be the focus of this article.

Medicare AWVs

The AWV, in particular, includes several unique aspects targeted at identifying and mitigating preventable health conditions for which enrollees are at risk. 13-15 The Medicare AWV is not the same as a routine physical examination, as the AWV typically lasts about 1 hour and has several components that must be fulfilled in order to claim reimbursement from Medicare Part B (Table 1). 13,15 One unique component required for the AWV is completion of a health risk assessment (HRA), which is used to gather patients' demographic information, self-assessment of health status, risk factors, and activities of daily living. 13,16 The HRA may be completed prior to or during the AWV appointment by telephone, mail, or in-person and takes no more than 20 minutes to complete. 13 A second unique component required for the AWV is the Personalized Preventive Plan of Services report. Although medications are reviewed and routine measures such as body mass index and blood pressure are assessed during the visit, the goal of each AWV is to create or update a personalized preventive care screening plan for the next 5 to 10 years for each patient, which is known as the Personalized Preventive Plan of Services report ("Patient Report"). 13,17 This screening schedule, or checklist, is constructed according to age- and condition-based guidelines and represents an opportunity for referral to and collaboration between multiple members of the health-care team, including physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists. 13

Uptake and Barriers Surrounding AWV Services

Since its creation in 2011, the uptake of the Medicare AWV has been slow. ^{13,17-19} In 2012, less than 10% of eligible beneficiaries received an AWV, and the rate has not improved much in recent years despite the fact that it is offered at no cost to Medicare enrollees. ^{15,17} Specifically, out of 33.1 million eligible beneficiaries throughout the United States in 2015, only 5.9 (17.7%) million received an AWV. ²⁰ Disparities also exist among geographical regions; for example, the rates of AWV provision were highest in the Northeastern states of Rhode Island (31.9%) and Massachusetts (30.7%) in 2015. ²⁰ On the other hand, fewer enrollees in Southern and Midwestern states, such as Alabama, Louisiana, and Iowa, tended to receive this service (13.8%, 9.4%, and 13%, respectively). ²⁰ This may be due to a complex mix of patient and provider barriers. ^{17,18,21-23}

In regard to patient-level barriers, individual and sociode-mographic factors affect access and uptake of preventive services, including AWVs. ^{17,18,21-23} Indeed, patient unfamiliarity with the AWV service plays a major role in limiting demand for and acceptance of AWV services ^{17,18}; emphasizing that Medicare Part B deductibles and coinsurance are waived for these services may help to increase uptake. ^{1,8,10} Furthermore,

previous studies documented disparities in receipt of preventive services, including AWVs, based on patients' race, ethnicity, education, and household income. Is, 21-23 In fact, blacks and individuals with lower income and education level are less likely to receive AWVs compared to whites and those with higher income and education. Is Given that health-care provider (physician or other ancillary provider) recommendation is one of the most important factors in determining patient uptake of preventive services, are methods to increase provider adoption and implementation of AWV services across all patient populations are crucial.

In regard to physician-level barriers, individual and system factors affect adoption and implementation of the service. 17,18 Physicians are often unfamiliar with AWVs in general as well as the multiple elements comprising an AWV, which in turn prevent them from offering AWVs to their patients. 17,18 In particular, and similar to many other preventive services, physicians are unfamiliar with "reverse engagement," that is, proactively contacting the beneficiary to initiate an AWV and/or previsit HRA rather than depending on the beneficiary to initiate a visit, thus limiting AWV service implementation to a smaller pool of patients. ^{17,18} Furthermore, system barriers play a key role, including: (1) lack of a structured template for performing the HRA, (2) difficulty incorporating the AWV into existing workflow, and (3) lack of time. 17,18 Given that providers are reimbursed about \$170 on average for initial AWVs and \$120 for subsequent AWVs (depending on state), not to mention reimbursement for additional age- or condition-appropriate screenings performed as a result of the AWV, there are multiple opportunities to sustain a thriving practice. 17 Thus, by finding strategies to overcome the aforementioned barriers, physicians can potentially increase practice revenue by over \$200 per completed AWV and improve the health outcomes of their patients.¹⁷ This represents an opportunity for allied health professionals to fill a gap in patient care and streamline the provision of care in their medical communities.

Strategies to Increase Uptake of AWV Services

Utilizing nonphysician, allied health professionals who are allowed to perform AWVs including nurse practitioners, physician assistants, registered nurses, and pharmacists is a strategy to efficiently overcome barriers to implementing AWVs in physician offices. 17,25 Allied health professionals already employed in physician clinics and working with the physician under a standing order or collaborative practice agreement (inhouse) can be trained to implement AWV services. 17 Another approach is for a physician office to contract (often at an hourly rate) with an allied health professional or a team of medical professionals (which may include management service organizations or MSOs) who come in from outside the organization to perform the AWV (outsource). 17 As long as they operate under the supervision of a physician (meaning that a physician is on the premises), these nonphysician medical professionals can perform AWVs and free up physician time. 13 Allied health

professionals can perform all aspects of the AWV as permitted by state law and clinic guidelines, including particularly time-consuming elements such as previsit phone calls and HRAs, scheduling, and recommendations/referrals for further preventive services in the Personalized Preventive Plan of Services report ("Patient Report"). This represents an opportunity for interprofessional collaboration, especially for pharmacists working in ambulatory care or community settings and looking to expand their practice.

Pharmacist-Delivered AWV Services

The Centers for Disease Control and Prevention (CDC) recommends pharmacists as an optimal choice for performing AWVs.²⁶ As long as they are working under the supervision of a physician, with patient care activities specified via standing order or collaborative practice agreement and conforming to state law, pharmacists can perform any part of the HRA or preventive assessment. The benefits of pharmacists performing AWVs have been shown in several studies.²⁷⁻²⁹ For example. the identification of inappropriate medications was doubled compared to nonpharmacist providers,²⁷ which not only improved care for older adult patients but also opened up additional reimbursement opportunities through Medicare Part B for more complex AWVs requiring extensive medication reconciliation/management using the 25-modifier Current Procedural Terminology code.²⁷ In general, patients and physicians were satisfied with pharmacist care, 28 and incorporating pharmacist-delivered AWVs into the workflow was found to free up physician and nurse practitioner time for other clinical tasks, improve appropriate medication management for patients, and increase revenue for clinics.²⁹ Importantly, incorporation of pharmacists as AWV service providers led to the implementation of additional profit-generating services such as medication therapy management (MTM)^{28,29} or chronic care management (CCM) services,²⁶ representing an additional opportunity to expand patient care and advance the clinical pharmacy field.

However, in order to capitalize on this opportunity and promote continued advances in clinical pharmacy and patient care, we need to understand current AWV adoption and implementation practices among pharmacists. This information may be useful for pharmacists working in outpatient or ambulatory care clinics and wanting to expand their services or for community pharmacists looking to adopt or implement AWV services in collaboration with local physician offices.

Objective

We focused on one strategy to increase AWV service implementation, namely, utilization of pharmacists as AWV service providers. Accordingly, the purpose of this article was to explore existing practice models and highlight practice opportunities surrounding pharmacist-delivered Medicare AWVs.

Data Sources

In order to obtain a broad picture of current pharmacist involvement in AWV delivery and existing pharmacist-based practice models, we conducted a scoping review³⁰ of existing literature and synthesized findings regarding development and/or implementation of pharmacist-delivered AWV. English-language articles published in peer-reviewed journals from January 2011 to March 2018 were obtained by searching PubMed and Google Scholar online databases using permutations of the terms "pharmacist/pharmacy," "Medicare," "Annual Wellness Visit," "develop/development," and "implement/implementation." Reference lists of published articles were also hand-searched to identify additional studies.

Study Selection and Data Extraction

Experimental, quasi-experimental, or observational studies were eligible for inclusion if they (1) described the development of a pharmacist-delivered AWV program in terms of resources or inputs and/or (2) described the implementation processes of a pharmacist-delivered AWV program as well as programmatic outcomes including uptake and delivery, interventions made, financial models, or patient/provider satisfaction. Systematic reviews, articles published outside the United States, and articles evaluating or describing AWVs delivered via team-based care (of which pharmacists were a member, but not the lead) were excluded from our review. Database searches were conducted by a single reviewer (L.A.H.), and final articles to be included in the review were discussed and confirmed with a second independent researcher (T.J.H.). To ensure consistency, data were extracted by one reviewer (L.A.H.), including study design, setting, population, inputs, processes, and programmatic outcomes. Our intention was not to systematically and exhaustively evaluate all published literature on the topic, but rather to gather information broadly representing the current practice landscape in order to characterize existing practice models with the goal of identifying opportunities for pharmacists to improve services for older adults and expand their own practices.

Data Synthesis

Eight articles were found describing the results of 6 unique studies matching our broad inclusion criteria (Table 2). 27-29,31-35 In 2 cases, additional results from the same study were published in separate articles. 28,33-35 All used observational study designs and were published in peer-reviewed journals between 2014 and 2017. The majority (4/6) of the studies were conducted in southern US states, including South Carolina, North Carolina, and Virginia, with one study conducted in Arizona and one in Maryland. Five studies took place in family or internal medicine clinic settings, with only one 32 in a community pharmacy setting. Furthermore, 5 studies reported results of pharmacist-delivered AWVs over a range of 3 to 10 months in a population of 66 to 308 Medicare patients; one

Table 2. Summary of Study Characteristics.

Study	Study Design	Setting	Study Period	Study Population
Alhossan et al ³¹	Retrospective single-center chart review (observational)	Accountable care organization (ACO) in a federally qualified health center in Arizona	3 months (October to December 2013)	308 AWV patients
Beliard and Merrey ²⁷	 Multicenter retrospective case—control study (observational) Intervention group: AWV patients seen by pharmacist Control group: AWV patients seen by PCP Primary outcome measure: number and type of medication and non-medication-related interventions made by pharmacists vs nonpharmacists 	medicine clinics in Maryland	l • 10 months (January 2015 to October 2015)	66 AWV patients
Evans et al ³²	 Program evaluation and cross-sectional survey (observational) Budget impact analysis 	 One independently owned community pharmacy and 6 family medicine practices in South Carolina 	frame not	 Key contacts at 6 family medicine clinics (office managers, clinical coordinators, or physicians)
Thomas ²⁹	 Retrospective single-center chart review (observational) 	One family practice office in Virginia	• 6 months (September 2012 to February 2013)	 174 AWV patients
^a Warshany et al ³³ ; Sherrill ³⁴	 Retrospective single-center chart review (observational) 	 One academic internal medicine clinic in North Carolina 	10 months (August 2011 to May 2012)	98 AWV patients
^b Wilson et al ²⁸ ; Park et al ³⁵	 Retrospective single-center chart review and cross-sectional survey²⁸ (observational) Financial analysis³⁵ 	 Multidisciplinary academic family medicine practice in North Carolina 	• 10 months (April	• 69 AWV patients

Abbreviations: EHR, electronic health record; FTE, full-time equivalent; MA, medical assistant; NP, nurse practitioner; PA, physician assistant; PCP, primary care provider

study³² reported AWV program development and implementation guidelines among a population of pharmacists and providers but did not deliver AWVs to patients. Inputs and resources (personnel, pharmacist full-time equivalents [FTEs], facilities, and expenses), implementation processes (pharmacist authority, identification of eligible patients, planned pharmacist interventions, HRA completion, workflow, and business operations), and programmatic outcomes (uptake and delivery, interventions made, economic impact, and patient/physician satisfaction) of these pharmacist-delivered AWV services are described in the following sections. Clinical outcomes of pharmacist-delivered AWVs were not reported in the included studies.

Inputs and Resources

Pharmacist-delivered AWV service inputs and resources were reported in all identified studies (Table 3). Service inputs were categorized into site personnel, pharmacist FTEs employed for AWVs, source of pharmacist personnel, and facilities and expenses. Studies varied in their reports of site personnel

involved in AWV services, with some discussing only pharmacist personnel³³ and others describing all staff members present at the site including physicians, nurse practitioners, physician assistants, registered nurses, receptionists, and ancillary staff.²⁹ The number of pharmacist personnel used to conduct services ranged from 1 to 2, with an average of 0.22 pharmacist FTEs dedicated to AWVs across all reported studies.^{29,32,33} Five studies utilized in-house pharmacist personnel (mean: 0.24 FTEs)^{29,33} and only 1 study outsourced pharmacist personnel (0.20 FTEs).³²

Furthermore, required facilities and/or expenses were reported in 4 of 6 studies, with main expenses including pharmacists' salary and time dedicated to AWVs (\$2600/quarter for pharmacy residents or \$7150/quarter for pharmacists).³² One study reported 160 total pharmacist hours (mean: 6.67 h/wk) expended during the first 6 months of AWV program development and implementation, with 40 hours (mean: 1.67 h/wk) of this spent on one-time development of AWV electronic health record (EHR) templates and approximately 5 h/wk devoted to AWV implementation.²⁹ Outsourced pharmacists reported additional nonsalary expenses including liability insurance,

^aUptake and delivery, intervention, and financial measures reported by Warshany; satisfaction measures reported by Sherrill.

^bUptake and delivery, intervention, and satisfaction measures reported by Wilson; financial measures reported by Park.

Table 3. Program Inputs and Resources.

		Inputs and Resourc	ces	Source of Pharmacist Personnel
Study	AWV Personnel	Pharmacist FTEs for AWVs	Facilities and Expenses	In- House Outsource
Alhossan et al ³¹	Clinical pharmacists (# not reported) employed by one ACO/federally qualified health center with 14 clinic locations serving over 80 000 patients per year	•	Not reported	✓
Beliard and Merrey ²⁷	2 clinical pharmacists employed by clinical to provide chronic disease state management (CCM) services; PCPs employed by clinics (mean 8/clinic); medical assistants (MAs); licensed practical nurses (LPNs)	s • Not reported	Not reported	✓
Evans et al ³²	I community pharmacy resident 4 d/mo I pharmacy resident program director; pharmacy owner; PCPs employed by local family medicine clinics (range of I-6 mean 3.5 providing AWV)		 Facilities: not reported Expenses: \$17 963/year (pharmacy resident salary \$52 000/year including benefits [pharmacist \$143 000/year]; liability insurance \$75/year; mileage to physician clinic \$576/year; clinical reference \$500/year; supplies \$105/year profit sharing with physician office \$6307.20/year); pharmacy resident time (45 minutes/AWV once per week) 	
Thomas ²⁹	I clinical pharmacist already employed by office to provide CCM and education programs (hours extended from 8 h/d, I day week to 16 h/wk); 2 physicians (I full time, I part-time); 3 NPs; I PA; 10 nurses; 2 receptionists; 7 ancillary staff	I	 Facilities: one practice office open 6 d/w with evening hours on 2 days. Examination room designated for the pharmacist Expenses: pharmacists' fixed hourly salary (monetary values not reported); pharmacist time (30-45 min/AWV); nurse time (3-5 min/visit); provider time (5-10 min/visit); mailing supplies (invitation letters and HRA forms); facility overhead. 160 pharmacist-hours used during first 6 months of service development and implementation (40 hours for one-time development of EH templates). 	e
^a Warshany et al ³³ ; Sherrill et al ³⁴ ^b Wilson et al ²⁸ ; Park et al ³⁵	 I clinical pharmacist practitioner (CPP) already employed by the clinic to provide chronic care management (CCM) I clinical pharmacist practitioner (CPP) already employed by the practice to provide CCM, comprehensive medication management, and patient education; at least I MA; I7 PCPs (total practice) 	Not reported	 Facilities: sixteen 40-minute time slots available for AWVs per month Expenses: not reported 	

Abbreviations: EHR, electronic health record; FTE, full-time equivalent; MA, medical assistant; NP, nurse practitioner; PA, physician assistant; PCP, primary care provider. ^aUptake and delivery, intervention, and financial measures reported by Warshany; satisfaction measures reported by Sherrill.

^bUptake and delivery, intervention, and satisfaction measures reported by Wilson; financial measures reported by Park.

mileage, and clinical reference materials totaling \$1890.75/ quarter.³²

Implementation Processes

Service processes were grouped into 6 categories: method of pharmacist authority, method to identify eligible patients, planned pharmacist interventions, HRA completion, workflow, and business operations (Table 4). Pharmacist authority was enabled via collaborative practice agreements in all reported cases. ^{28,31-35} In 2 studies in North Carolina, pharmacists were able to perform additional medication adjustments via advanced practice certification authority, and one study also reported the development of standing orders specifically for pharmacist-delivered AWV services. ^{28,35}

Methods to identify patients who were eligible for AWVs included: screening medical charts for age ≥66 years and sending mailed invitations (eligibility for the initial AWV begins 1 year after enrollment in Medicare Part B, with typical enrollment at age 65); flagging eligible patients in the EHR prior to scheduled appointments; primary care provider referral to pharmacists; and patient request. Practices using medical charts to screen for eligibility combined with mailed invitations were most successful in recruiting patients for AWV appointments.²⁹ Planned AWV interventions included medication- and non-medication related interventions such as medication adjustments, ordering lab tests, providing referrals for preventive screenings, and vaccination recommendations. HRAs were mailed to patients to complete prior to the AWV in 2 studies^{29,33,34} and completed in the office after check-in on the day of the visit in 2 studies, ^{27,29} with entry of responses into the EHR by a pharmacist or nurse mentioned in 2 studies.^{27,29} Scheduled appointment times ranged from 30 to 45 minutes, with provision of pharmacist-delivered AWV services once weekly for 8 h/d in reported cases. 29,32

In regard to business operations, only one study reported specific steps taken to build a collaborative AWV practice between a pharmacist and physician office, with an explicit business plan for pharmacist-physician profit sharing. Six steps undertaken to form this business proposal/plan included: pharmacist self-learning, needs assessment of the local area, creation of a marketing kit, making initial contact with potential business partners (physician offices), meeting with interested contacts, and developing a contractual/collaborative practice agreement. A key part of the marketing and contractual discussions involved creation of a profit-and-loss projection, which is a tool used to predict financial profits from the AWV service over specified time frames.

Programmatic Outcomes

Programmatic outcomes were grouped into 4 categories: uptake and delivery, interventions made, economic, and patient/physician satisfaction (Table 5). No included studies described patients' clinical outcomes resulting from pharmacist-delivered AWV implementation. Five of the 6

included studies were able to conduct AWVs, ranging from 37 to 300 AWVs completed by pharmacists. Evans et al projected 292 AWVs per year, but a collaborative agreement between the authors' community pharmacy setting and a physician's office was not able to be made and thus no AWVs were able to be conducted; perceived lack of time, resources, or legal issues were reported as reasons why physician offices decided not to collaborate with the pharmacy.³² As a result of the AWVs completed by pharmacists in these studies, a variety of interventions were made, with the average number of interventions ranging from 3.5 to 5.4 per patient. The majority of pharmacists' interventions were referrals to other specialty providers (nutrition, audiology, etc) and referrals/orders for additional procedures (mammography, colon cancer screening, etc). Additional interventions included laboratory tests ordered, vaccinations offered, education provided, and medication and dosage changes. Further, Thomas incorporated MTM into each AWV, ²⁹ and 3 studies discussed adding AWV services to existing pharmacotherapy or CCM clinic visits, 27,28,33 increasing the reimbursement potential of each visit.

The total quarterly revenue from completed AWVs utilizing in-house pharmacists ranged from \$3750 to \$22340, with one study reporting total quarterly revenue from ancillary services provided during the AWV of \$36379.^{31,35} Evans et al projected that outsourcing pharmacists from community pharmacies would result in quarterly revenue of \$7884 (7.5-10 AWVs/d, 1 d/week) with a 60/40 pharmacy/clinic profit share needed for minimum profitability for both parties.³²

Additionally, 2 studies examined patient satisfaction with the AWVs, ^{28,34} reporting that over 70% of patients were very satisfied with the pharmacist-delivered AWV overall and over 80% agreed or strongly agreed that they would like to see the same provider for their AWV again the following year. Wilson et al also examined physician satisfaction, reporting that, on average, physicians agreed that patients were willing to see a pharmacist for the AWV. Physicians also strongly disagreed that they preferred to conduct the AWVs themselves as opposed to pharmacists conducting the AWVs. ²⁸

Implications for Patient Care and Clinical Practice

Despite being offered at no cost to Medicare enrollees, the percentage of Medicare patients receiving an AWV remains low at less than 20% nationally. The potential barriers to increased uptake include a lack of awareness and understanding of the AWV among patients, physicians, and other prescribers, as well as the time-consuming nature of the AWV and its disruption to physicians' workflow. In order to overcome these barriers, recommendations have been made to incorporate pharmacists who can conduct these visits under a physician's supervision. However, a scoping review of the literature found only 6 studies reporting development and implementation of pharmacist-delivered AWV services to date, which shows that the development of this role for pharmacists is still in its infancy. Proceedings of the store of the pharmacists is still in its infancy.

 Table 4. Program Implementation Processes.

	Processes											
Study		narmacist uthority		tient entification		armacist terventions	HF	RA Completion	W	orkflow		siness perations
Alhossan et al ³¹	•	Collaborative practice agreement within accountable care organization (ACO)	•	Not reported	•	Medication and non-medication-related interventions; order lab tests; referrals for preventive screenings; provide preventive services like vaccinations; make medication changes	•	Not reported	•	Pharmacist conducted AWVs; primary care physician (PCP) seen for AWV by referral only	•	Not reported
Beliard and Merrey ²⁷	•	Specified NO collaborative practice agreement (specific method not reported)	•	I. MA or LPN identified and flagged in EHR patients eligible for AWV the day prior to already-scheduled PCP or pharmacist visits; or 2. Outreach to patients on a list of overdue AWVs (method of outreach not specified)	•	Address medication and non-medication- related concerns identified in HRA	•	Developed own paper HRA form to scan/enter into EHR. Patient completed paper HRA in waiting room after checking in for AWV appointment. HRA data entered into EHR by nurse or MA for PCP-delivered AWVs and by pharmacist for pharmacist.	•	AWV conducted at the same time as regular appointment (time not extended, 15-30 minutes for PCPs, 30 minutes for pharmacists). Standard AWV progress note template used in EHR. All pharmacist AW and Vs and interventions or referrals cosigned by PCPs	•	Not reported
Evans et al ³²	•	Collaborative practice agreement	•	Not reported	•	Not reported	•	delivered AWVs Not reported	•	Proposed AWV workflow: community pharmacy resident performs 45-minute AWVs at physician practice site I d/wk with 8-hour work day (max 10-11 AWVs/day)		6 steps developed to collaborate wit physician office Self-learning. Educate pharmacy personnel on AWV basics Needs assessment. Identify physician office within 15 miles of pharmacy ar assess current AWV provision using Medicare Provider Utilization and Payment Database

Table 4. (continued)

	Processes							
Study	Pharmacist Authority	Patient Identification	Pharmacist Interventions	HRA Completion	Workflow	Business Operations		
						 3. Create marketing kit to present to physician offices 4. Make initial contact with target offices by telephone. Pharmacist should first contact office 		
						manager 5. Contact each physician office to set up a meeting via phone, e-mail, or in-person. Inperson found to be most		
						effective 6. Collaborate with physician office. Develop collaborative practice agreement and financial plan. Set goal start date and plan		
						training 2 financial models developed using percent share between pharmacy and physician office. Profit-and-loss projection created using 80/ 20 pharmacy/ office split of AWV profit; for use in contractual		
Thomas ²⁹	Not specifie	d • EHR used to identify patient >66 with no AWV billed in previous year. Letters of invitation sent identified patie every month	non-medication related concer identified in HF medication to therapy	n- ns	Pharmacist conducted 30-45 minutes of AWVs I d/wk; PCP seen for AWV by referral only. MTM incorporated into AWV. Next	discussions Not reported		

Table 4. (continued)

	Processes							
Study	Pharmacist Authority	Patient Identification	Pharmacist Interventions	HRA Completion	Workflow	Business Operations		
^a Warshany et al ³³ ; Sherrill et al ³⁴	Collaborative practice agreement; advanced practice certification authority (CPP)	 Medicare patients over 65 were sent AWV invitations by mail (unclear if any screening was performed to determine AWV eligibility based on ≥ I year of enrollment in 	non-medication- related	Created customized paper HRA form for patients to complete at home before the visit or in the waiting room. Nurse entered HRA results into EHR template Scheduled patients were sent HRA packet via mail to complete prior to AWV	AWV automatically scheduled for thr following year. AWV progress notes co-signed by PCP. Diagnosis code V0.70 (routine examination without symptoms) billed • 40-minute time slots for AWVs. Pharmacist reviewed HRA packet and made interventions	Not reported		
°Wilson et al ²⁸ ; Park et al ³⁵	Collaborative practice agreement; advanced practice certification authority (CPP); standing orders	I. PCP referral to pharmacist for AWV; or 2. Patient request	education; complete referrals; administer vaccines		Pharmacist conducted 30- minute AWVs upon PCP referral or patient request. If vaccines ordered by pharmacist, they were administered by an MA. Comprehensive medication management services offered at same time as AWV as an additional service			

Abbreviations: EHR, electronic health record; FTE, full-time equivalent; MA, medical assistant; NP, nurse practitioner; PA, physician assistant; PCP, primary care provider aUptake and delivery, intervention, and financial measures reported by Warshany; satisfaction measures reported by Sherrill.

^bUptake and delivery, intervention, and satisfaction measures reported by Wilson; financial measures reported by Park.

 Table 5. Programmatic Outcomes.

	Programmatic Outcomes							
Study	Uptake and Delivery	Interventions Made	Economic ^a	Satisfaction				
Alhossan et al ³¹	300 AWVs completed by pharmacists	 I 608 AWVs interventions made (mean: 5.4 interventions/patient) 272 referrals made (ophthalmology > mammography > colon cancer screening > DEXA) I 83 laboratory tests ordered for diabetes and lipid screening 370 vaccinations offered (influenza > shingles > pneumococcal > Tdap) 24 medication and dosage changes 45%, 83% (P < .0001), and 49% (P < .001) of all referrals, laboratory tests, and vaccinations, respectively, were completed within 1 month of the visit 	 Quarterly revenue from AWVs: \$22 340 Quarterly revenue from ancillary services during AWV: \$36 379 	Not reported				
Beliard and Merrey ²⁷	 37 AWVs completed by pharmacists 43 AWVs completed by nonpharmacists (PCPs) 	 Pharmacists made 37 medication-related interventions PCPs made 20 medication-related interventions Pharmacists made more medication-related interventions/patient compared to PCPs (median 2 vs 0, P < .00001). Pharmacists made 61 (median: 5/patient) non-medication-related interventions versus PCPs made 60 (median: 2/patient) (P < .0013) Median 3.5 interventions/ patient overall Additional pharmacist services resulting from AWV: 31% of all pharmacistled AWVs resulted in PCP referrals to pharmacist medication management 	Not reported	Not reported				
Evans et al ³²	 Pharmacist met with 3/6 physician offices 0 physician offices adopted the pharmacy AWV service 	clinic ● N/A	 Reported projected revenue from AWVs: \$31 536/year Quarterly revenue from AVWs: \$7884 Projected pharmacy net profit: \$13 572/year Projected physician office net profit: \$6307.20/year 	• N/A				

Table 5. (continued)

	Programmatic Outcomes								
Study	Uptake and Delivery	Interventions Made	Economic ^a	Satisfaction					
Thomas ²⁹	 Physician offices cited perceived lack of time, resources, or legal issues as reasons for not adopting the pharmacy AWV service Projected number of AWVs = 292/year > 2000 eligible patients identified 	 Additional pharmacist services resulting from 	 Minimum profitable pharmacy/office split using pharmacy resident AWV delivery = any split other than 50/50 Minimum profitable pharmacy/office split using pharmacist AWV delivery = 60/40 (7.5-10 AWVs/day, 4 d/mo) Reported revenue from AWVs: \$27 880.98/6 	Not reported					
	 150-200 letters of invitation sent to eligible patients every month 174 AWVs completed 	AWVs: medication therapy management (MTM) incorporated into all AWVs	months • Quarterly revenue from AWVs: \$13, 940.49						
bWarshany et al ³³ , Sherrill et al ³⁴	 3281 eligible patients identified 2106 eligible patients invited to AWV; 98 patients (4.6%) accepted invitation to schedule AWV 98 AWVs completed Mean AWV appointment time of 73 minutes (check-in to check-out) 	 441 interventions made Mean: 4.5 interventions/ AWV 98 referrals made to other providers (most often nutrition, physical therapy, audiology) 91 education interventions (mean 1.4/AWV): 62% for home safety concerns; 27% for advance directives; and 4% for smoking cessation 97 lab tests or procedures ordered 125 vaccinations recommended and 28% administered: 19 tetanus, 9 pneumococcal, 7 influenza); herpes zoster recommended but not given 4 patients prescribed new medications based on HRA results 	Reported projected revenue from AWVs: expected total revenue of \$15 619.24/10 months based on reimbursement of \$159.38/initial AWV and \$106.35/subsequent AWV (actual revenue not reported) Quarterly revenue from AWVs: \$4685.77	 100% survey response rate 72% of patients were very satisfied with the care they received from the CPP (n = 46, mean 4.7 where I = very dissatisfied and 5 = very satisfied) 70% of patients were very satisfied with the visit as a whole (mean 4.6 where I = very dissatisfied and 5 = very satisfied) 98% of patients agreed or strongly agreed that they were comfortable discussing their health information with a CPP (mean 4.4 where I = strongly disagree and 5 = strongly agree) 87% of patients agreed or strongly agreed that they were just as comfortable discussing their health information for this visit with a CPP as with their PCP and that they would like to see the same provider next year (mean 4.1 where I = strongly disagree and 5 = strongly agree) 35% of patients agreed or strongly agreed that they would rather see their PCP for the AWV, while 44% of patients disagreed (mean 3.0 where I = strongly disagree and 5 = strongly disagree 					

(continued)

Table 5. (continued)

		Programmatic Outcomes					
Study	Uptake and Delivery	Interventions Made	Economic ^a	Satisfaction			
cWilson et al ²⁸ ; Park et al ³⁵	• 69AWVs completed	 589 total interventions made 247 medication-related interventions (mean 3.6/ patient) 342 non-medication-related interventions (mean 4.9/ patient) Mean 4.25 interventions/ patient overall Most frequent medication-related intervention: correcting medication list discrepancies (69.6%) Most frequent non-medication-related intervention: ordering or prescribing a vaccine (28.4%, mean: 1.4 vaccines/patient); referral to PCP for advance care planning (17%) Patients' number of medications positively associated with number of medication-related interventions (r = 0.37, P < .01) but not with total number of interventions (r = -0.13, P = .14) 	 Reimbursement/AWV: \$162.15/initial and \$107.25/subsequent Reported revenue from AWVs: \$10 000/8 months (2.4 AWVs/clinic half-day required to support pharmacist salary) Quarterly revenue from AWVs: \$3750 Hypothetical AWV utilization rates needed to support pharmacist salary based on varying practice sizes (assuming 10/90% initial/subsequent AWVs): small-size practice = 100%; medium-size practice = 54%; large-size practice = 18%; regardless of practice size = 1070 AWVs/year (2.9 visits/clinic half-day) 	 62.7% patient and 100% physician survey response rates Patients were very satisfied with the AWVs on average (n = 32, mean 4.7 where I=very dissatisfied and 5=very satisfied) Patients were neutral about whether they preferred to see a PCP or pharmacist for the AWV (mean 2.8 where I=strongly disagree and 5=strongly agree) Patients strongly agreed that they would like to see the same provider (pharmacist) again for their AWV the following year (mean 4.8 where I=strongly disagree and 5=strongly agree) Physicians agreed that patients were willing to see a pharmacist for the AWV (n=10, mean 4.2 where I=strongly disagree and 5=strongly agree) Physicians strongly disagree and 5=strongly agree Physicians strongly disagree and 5 = strongly agree Physicians strongly agree 			

Abbreviations: CPP, clinical pharmacist practitioner; EHR, electronic health record; FTE, full-time equivalent; MA, medical assistant; NP, nurse practitioner; PA, physician assistant; PCP, primary care provider.

provide preliminary guidance to pharmacists who are interested in providing AWVs as they consider resources, implementation plans, and indicators for measuring success. Furthermore, although the articles included in this review were limited to the United States due to a focus on the Medicare payment system, pharmacists and health-care practitioners in other countries can learn from the discussed implementation strategies and adapt them to their own practices in the context of their country's health-care system in order to streamline services for the older adult population.

Pharmacist-delivered AWV practice models identified in this review primarily differed based on utilization of in-house versus outsourced pharmacist personnel. The decision to choose between in-house versus outsourcing mechanisms is common among business practices; these decisions sometimes are referred to as "make-or-buy" decisions.³⁸ The majority of included studies utilized an in-house model by using clinical pharmacists who were the current staff of the clinics. Utilizing in-house pharmacists who already function as an employee overcomes many of the barriers to physician and pharmacist

aln cases where revenue was not reported quarterly, quarterly revenue was calculated from reported values for purposes of comparison across studies.

^bUptake and delivery, intervention, and financial measures reported by Warshany; satisfaction measures reported by Sherrill.

^cUptake and delivery, intervention, and satisfaction measures reported by Wilson; financial measures reported by Park.

collaboration. Pharmacists embedded within the care team have the advantage of being able to communicate more frequently with the physician, either verbally or electronically, developing greater trust within the team that is often difficult to achieve when outsourced. Further, this model allows the pharmacist-delivered service to be integrated into the site's workflow, with same-day co-visits being more convenient for both patients and physicians. From the organizational perspective, the in-house model allows for greater degree of integration of the service to its core functions, which in turn increases its sustainability. This model may therefore be very useful for pharmacists practicing in ambulatory care settings and wishing to enhance their clinical services.

While in-house pharmacists may be the most commonly used mechanism among the identified studies, outsourcing AWV delivery to community pharmacists is a viable approach, especially for clinics that do not have a staff pharmacist or are located in underserved or rural areas. 42 As only one study identified in this review reported creation of an AWV service in a community pharmacy setting, this also represents a gap or niche that can be filled by community pharmacists. For example, collaborative practice agreements (defined as formalized arrangements between physicians and pharmacists that give pharmacists the ability to perform a wide array of patient care services)⁴³ between a pharmacy and a local physician can be established to offer a community pharmacy AWV service, as described by Evans and colleagues.³² Despite interest in the program, clinics did not adopt the community pharmacistdelivered AWV program due to lack of an established collaborative relationship with the pharmacy.³² Therefore, in addition to methods of developing and implementing new AWV services in the community pharmacy setting, education on the process of establishing a working relationship between community pharmacists and local medical clinics is warranted. The CDC guidelines detailing implementation of pharmacistphysician collaborative practice agreements may aid in this endeavor. 44 This guide highlights methods to approach prescribers and the activities needed to create a functional clinical and business partnership, including: (1) meeting with clinic managers to discuss pharmacists' contribution toward improved clinical and financial quality metrics, (2) modifying a template to specify allowed clinical services performed by the pharmacist, and (3) registering the agreement with the state Board of Pharmacv.44

In order to optimally implement pharmacist-delivered AWV services and form interprofessional collaborations, however, the broader health policy environment must be understood. As pharmacists cannot independently bill for the provision of an AWV unless they are under the direct supervision of a physician, collaborative practice agreements will be required for most community pharmacists interested in providing AWVs. Laws governing collaborative practice agreements can vary between states. Pharmacists interested in establishing a collaborative relationship should first seek to understand the policies surrounding these agreements within their state and identify prescribers with whom a relationship can be built. 44

The templates and financial models described within the studies in this review may be helpful to ambulatory care and community pharmacists in demonstrating the advantages of physician-pharmacist collaboration in order to facilitate uptake of AWV services. Pharmacists and other health-care professionals wishing to learn more about AWVs and preventive services reimbursed by Medicare may find the education materials provided by the Centers for Medicare and Medicaid Services Medicare Learning Network useful. Moving forward, policy changes allowing pharmacists to be recognized as providers would enable pharmacists to more easily deliver services such as the AWV, which they are ideally suited to implement in the community setting.

Conclusions

Although uptake of Medicare AWVs has been slow across the United States, novel pharmacist-physician practice models exist to guide those wanting to implement their own AWV services. The current practice landscape is dominated by AWV services utilizing in-house clinical pharmacists delivering care within internal or family medicine clinics. However, there is opportunity for community pharmacists to expand their practice to include AWV services in states allowing collaborative practice agreements, which may help increase access and uptake of AWVs among older adults. Pharmacists working in ambulatory care settings may also find the AWV practice models highlighted in this review of use in enhancing their own services. Further pharmacist and physician education is needed to promote interprofessional collaboration and aid adoption of pharmacist-delivered AWV services.

Authors' Note

This work was submitted as an abstract for poster presentation at the Southern Pharmacy Administration Conference (SPAC) held June 7-9, 2018.

Acknowledgments

The authors would like to thank the Alabama Department of Senior Services (ADSS) for their support of this investigation through a grant from the Administration for Community Living (ACL) [grant no. G00011145]. Funders played no role in manuscript preparation.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Supported through a grant from the Administration for Community Living (ACL) [grant no. G00011145].

References

1. Centers for Disease Control and Prevention. Preventive Health Care. Gateway to Health Communication. 2017. https://www.

cdc.gov/healthcommunication/toolstemplates/entertainmented/tips/PreventiveHealth.html. Accessed February 7, 2018.

- 2. Hoffman C, Rice D, Sung H. Persons with chronic conditions: their prevalence and costs. *JAMA*. 1996;276(18):1473-1479.
- Ward BW, Schiller JS, Goodman RA. Multiple chronic conditions among US adults: a 2012 update. Prev Chronic Dis. 2014;11:E62.
- Centers for Disease Control & Prevention. Chronic Disease Overview. 2017. https://www.cdc.gov/chronicdisease/overview/index. htm. Accessed February 7, 2018.
- Gerteis J, Izrael D, Deitz D, et al. Multiple Chronic Conditions Chartbook. Rockville, MD: Agency for Healthcare Research and Quality Publications; 2014. www.ahrq.gov/sites/default/files/ wysiwyg/professionals/prevention-chronic-care/decision/mcc/ mccchartbook.pdf. Accessed February 7, 2018.
- Anderson G, Horvath J. The growing burden of chronic disease in America. *Public Health Rep.* 2004;119(3):263-270.
- Ward JE, Gordon J, Sanson-Fisher RW. Strategies to increase preventive care in general practice. *Med J Aust*. 1991;154(8): 523-531
- 8. Trivedi AN, Rakowski W, Ayanian JZ. Effect of cost sharing on screening mammography in Medicare health plans. *N Engl J Med*. 2008;358(4):375-383.
- 9. Solanki G, Schauffler HH, Miller LS. The direct and indirect effects of cost-sharing on the use of preventive services. *Health Serv Res.* 2000;34(6):1331-1350.
- 10. Solanki G, Schauffler HH. Cost-sharing and the utilization of clinical preventive services. *Am J Prev Med.* 1999;17(2):127-133.
- 11. Koh HK, Sebelius KG. Promoting prevention through the Affordable Care Act. *N Engl J Med*. 2010;363(14):1296-1299.
- Centers for Medicare and Medicaid Services. The ABCs of the initial preventive physical exam (IPPE). *Medicare Learning Net*work. 2017. https://www.cms.gov/Outreach-and-Education/Medi care-Learning-Network-MLN/MLNProducts/downloads/MPS_ QRI_IPPE001a.pdf. Accessed December 7, 2017.
- Centers for Medicare and Medicaid Services. The ABCs of the Annual Wellness Visit (AWV). *Medicare Learning Network*.
 https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/MLN-Publications-Items/CMS1246474.html. Accessed 12/04/2017 10:49 AM.
- American Academy of Family Physicians. Get Paid with the Annual Wellness Visit. 2018. https://www.aafp.org/practice-man agement/payment/coding/medicare-coordination-services/awv. html. Accessed March 20, 2018.
- 15. Bluestein D, Diduk-Smith R, Jordan L, Persaud K, Hughes T. Medicare annual wellness visits: how to get patients and physicians on board. *Fam Pract Manag.* 2017;24(2):12-16.
- 16. Hughes C.Medicare annual wellness visits: don't forget the health risk assessment. *Fam Pract Manag.* 2012;19(2):11-14.
- 17. Rouhbakhsh R, Green R. The annual wellness visit: why Medicare's no-cost preventive benefit isn't getting the attention it deserves and how to maximize reimbursements without disrupting your workflow. 2015. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=7&ved=0ahUKEwjwlJP_qfHYAhVBt1MKHc3dAvAQFghWMAY&url=https%3A%2F%2Fwww.awvsolution.com%2Fdocuments%2FWhite_Paper_The_Annual_Wellness_Vist_August_2015.pdf&usg

- =AOvVaw2Av6D03YSyJWyWqMWdCaSd. Accessed January 24, 2018.
- Hu J, Jensen GA, Nerenz D, et al. Medicare's annual wellness visit in a large health care organization: who is using it? *Ann Intern Med*. 2015;163(7):567-568.
- 19. Galvin SL, Grandy R, Woodall T, et al. Improved utilization of preventive services among patients following team-based annual wellness visits. *N. C. Med J.* 2017;78(5):287-295.
- Centers for Medicare and Medicaid Services. More than 10 million people with Medicare have saved over \$20 billion on prescription drugs since 2010. 2016. https://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-releases/2016-Press-releases-items/2016-02-08.html. Accessed January 24, 2018.
- Sambamoorthi U, McAlpine DD. Racial, ethnic, socioeconomic, and access disparities in the use of preventive services among women. *Prev Med.* 2003;37(5):475-484.
- Benjamins MR, Kirby JB, Huie SAB. County characteristics and racial and ethnic disparities in the use of preventive services. *Prev Med*. 2004;39(4):704-712.
- 23. Chen JY, Diamant A, Pourat N, et al. Racial/ethnic disparities in the use of preventive services among the elderly. *Am J Prev Med*. 2005;29(5):388-395.
- Ylitalo KR, Lee H, Mehta NK. Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US national immunization survey. *Am J Public Health*. 2013; 103(1):164-169.
- 25. Waltz TJ, Powell BJ, Matthieu MM, et al. Use of concept mapping to characterize relationships among implementation strategies and assess their feasibility and importance: results from the Expert Recommendations for Implementing Change (ERIC) study. *Implement Sci.* 2015;10(1):109.
- Garwood CL, Korkis B, Mohammad I, et al. Implementation of chronic care management services in primary care practice. Am J Health Syst Pharm. 2016;73(23):1924-1932.
- Beliard RC, Merrey JW. Evaluation of interventions in clinical pharmacist-led annual Medicare wellness visits compared with usual care. *Consult Pharm*. 2017;32(11):687-699.
- 28. Wilson CG, Park I, Sutherland SE, et al. Assessing pharmacistled annual wellness visits: interventions made and patient and physician satisfaction. *J Am Pharm Assoc* (2003). 2015;55(4): 449-454.
- 29. Thomas MH. Development and implementation of a pharmacist-delivered Medicare annual wellness visit at a family practice office. *J Am Pharm Assoc* (2003). 2014;54(4):427-434.
- Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. *Health Info Libr J*. 2009;26(2):91-108.
- 31. Alhossan A, Kennedy A, Leal S. Outcomes of annual wellness visits provided by pharmacists in an accountable care organization associated with a federally qualified health center. *Am J Health Syst Pharm.* 2016;73(4):225-228.
- 32. Evans TA, Fabel PH, Ziegler B. Community pharmacist—delivered Medicare annual wellness visits within a family medicine practice. *J Am Pharm Assoc* (2003). 2017;57(3): S247-S251.

- Warshany K, Sherrill CH, Cavanaugh J, et al. Medicare annual wellness visits conducted by a pharmacist in an internal medicine clinic. Am J Health Syst Pharm. 2014;71(1):44-49.
- Sherrill CH, Cavanaugh J, Shilliday BB. Patient satisfaction with Medicare annual wellness visits administered by a clinical pharmacist practitioner. *J Manag Care Spec Pharm*. 2017;23(11): 1125-1129.
- 35. Park I, Sutherland SE, Ray L, et al. Financial implications of pharmacist-led Medicare annual wellness visits. *J Am Pharm Assoc* (2003). 2014;54(4):435-440.
- Ganguli I, Souza J, McWilliams JM, et al. Trends in use of the US Medicare annual wellness visit, 2011-2014. *JAMA*. 2017;317(21): 2233-2235.
- Goetzel R, Staley P, Ogden L, et al. A framework for patient-centered health risk assessments—providing health promotion and disease prevention services to Medicare beneficiaries. 2011. https://www.cdc.gov/policy/hst/hra/frameworkforhra.pdf. Accessed March 22, 2018.
- Miles RE, Snow CC. Designing strategic human resources systems. Organ Dyn. 1984;13(1):36-52.
- 39. Moreno G, Lonowski S, Fu J, et al. Physician experiences with clinical pharmacists in primary care teams. *J Am Pharm Assoc* (2003). 2017;57(6):686-691.

- 40. Williams CR, Woodall T, Wilson CG, et al. Physician perceptions of integrating advanced practice pharmacists into practice. *J Am Pharm Assoc* (2003). 2018;58(1):73-78.e72.
- 41. Westrick SC. Forward and backward transitions in pharmacy-based immunization services. *Res Social Adm Pharm.* 2010; 6(1):18-31.
- Yoshizuka K, Knapp KK, Shane PA, et al. Inserting pharmacists in primary care roles in an ambulatory care setting. *California J Health Syst Pharm*. 2015;27(1):15-28.
- 43. Benjamin M; American Pharmacists Association Foundation, American Pharmacists Association. Consortium recommendations for advancing pharmacists' patient care services and collaborative practice agreements. J Am Pharm Assoc. 2013;53(2): e132-e141.
- 44. Centers for Disease Control & Prevention. Advancing team-based care through collaborative practice agreements: a resource and implementation guide for adding pharmacists to the care team. 2017. https://www.cdc.gov/dhdsp/pubs/docs/CPA-Team-Based-Care.pdf Accessed February 8, 2017.
- Centers for Medicare and Medicaid Services. Medicare Learning Network. 2018. https://www.cms.gov/Outreach-and-Education/ Medicare-Learning-Network-MLN/MLNGenInfo/index.html. Accessed October 3, 2018.